Fax: +33-1-42-11-40-00
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Epidemiology
You have full text access to this OnlineOpen article
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort
Article first published online: 18 NOV 2004
DOI: 10.1002/ijc.20710
Copyright © 2004 Wiley-Liss, Inc.
Additional Information
How to Cite
Fournier, A., Berrino, F., Riboli, E., Avenel, V. and Clavel-Chapelon, F. (2005), Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer, 114: 448–454. doi: 10.1002/ijc.20710
Publication History
- Issue published online: 8 FEB 2005
- Article first published online: 18 NOV 2004
- Manuscript Accepted: 12 AUG 2004
- Manuscript Received: 12 MAY 2004
Funded by
- French League against Cancer
- European Community
- 3M Company
- Mutuelle Générale de l'Education Nationale
- Institut Gustave-Roussy
- Institut National de la Santé et de la Recherche Médicale
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , Changing Concepts: Menopausal Hormone Therapy and Breast Cancer, JNCI Journal of the National Cancer Institute, 2012,
- 2, Micronized progesterone and its impact on the endometrium and breast vs. progestogens, Climacteric, 2012, 15, S1, 18
- 3, , , , , , , , , , , PPARgamma-PGC-1alpha activity is determinant of alcohol related breast cancer, Cancer Letters, 2012, 315, 1, 59
- 4, , , , , , , , , , , , , , , , Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women, Contraception, 2011,
- 5, , , High burden of breast cancer in Belgium: recent trends in incidence (1999-2006) and historical trends in mortality (1954-2006), Archives of Public Health, 2011, 69, 1, 2
- 6Hormone Replacement Therapy and Breast Cancer in Postmenopausal Women, The Journal of Korean Society of Menopause, 2011, 17, 3, 125
- 7, , Hormone Replacement Therapy in the Geriatric Patient: Current State of the Evidence and Questions for the Future. Estrogen, Progesterone, Testosterone, and Thyroid Hormone Augmentation in Geriatric Clinical Practice: Part 1, Clinics in Geriatric Medicine, 2011, 27, 4, 541
- 8, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition, International Journal of Cancer, 2011, 128, 1Direct Link:
- 9, Postmenopausal Hormone Therapy and Breast Cancer Risk: Current Status and Unanswered Questions, Endocrinology & Metabolism Clinics of North America, 2011, 40, 3, 509
- 10, , A review of the cardiovascular and breast actions of drospirenone in preclinical studies, Climacteric, 2010, 13, 1, 22
- 11, , , Caractéristiques individuelles et mortalité associées au traitement hormonal substitutif de la ménopause : étude d’une cohorte française de femmes d’âge compris entre 60 et 69 ans, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 2010, 39, 6, 453
- 12, , , , , , Discontinuation of hormone therapy in the French GAZEL cohort 1990–2006, Fertility and Sterility, 2010, 94, 4, 1387
- 13, , , , , , , , , , , Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women, Climacteric, 2010, 13, 5, 433
- 14, , , , , , Long-term endometrial and breast safety of a specific, standardized soy extract, Climacteric, 2010, 13, 4, 368
- 15, , Menopause management: a cardiovascular risk-based approach, Climacteric, 2010, 13, 4, 328
- 16, , , , , Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts, Menopause, 2010, 1
- 17, Quelles hormones promeuvent le cancer du sein en post-ménopause : estrogènes, progestatifs, insuline et/ou adipocytokines ?, Gynécologie Obstétrique & Fertilité, 2010, 38, 1, 1
- 18, The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease, European Journal of Cancer Prevention, 2010, 19, 4, 256
- 19, , The Role of Sex Steroid Receptors on Lipogenesis in Breast and Prostate Carcinogenesis: A Viewpoint, Hormones and Cancer, 2010, 1, 2, 63
- 20, , , , , , Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns, Climacteric, 2010, 13, 5, 442
- 21, , , , Densité mammaire : un paramètre à surveiller lors de la prise d’un traitement hormonal de la ménopause, Gynécologie Obstétrique & Fertilité, 2009, 37, 7-8, 657
- 22, , , , Endometriosis risk in relation to naevi, freckles and skin sensitivity to sun exposure: the French E3N cohort, International Journal of Epidemiology, 2009, 38, 4, 1143
- 23, , , , , Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17Â -estradiol and norethisterone when compared with an orally administered 17Â -estradiol norethisterone regimen, Human Reproduction, 2009, 24, 7, 1739
- 24, , , , How to evaluate the calibration of a disease risk prediction tool, Statistics in Medicine, 2009, 28, 6Direct Link:
- 25, Le traitement hormonal de la ménopause : après sept ans de polémiques, Médecine & Longévité, 2009, 1, 1, 31
- 26
- 27, , , Patterns of hormone therapy use in the Norwegian Women and Cancer study (NOWAC) 1996–2005, Maturitas, 2009, 63, 3, 220
- 28, , , , , , Progestins induce catalase activities in breast cancer cells through PRB isoform: Correlation with cell growth inhibition, The Journal of Steroid Biochemistry and Molecular Biology, 2009, 115, 3-5, 153
- 29
- 30
- 31
- 32, Cancérogenèse hormonale chez la femme : des mécanismes à la prévention, Comptes Rendus Biologies, 2008, 331, 2, 104
- 33, Contre la médicalisation de la ménopause avec le THM, Gynécologie Obstétrique & Fertilité, 2008, 36, 1, 104
- 34, , , , Could transdermal estradiol+progesterone be a safer postmenopausal HRT? A review, Maturitas, 2008, 60, 3-4, 185
- 35, , , , Estrogen and SERM neuroprotection in animal models of Parkinson's disease, Molecular and Cellular Endocrinology, 2008, 290, 1-2, 60
- 36, , , , Hormone replacement therapy use and variations in the risk of breast cancer, BJOG: An International Journal of Obstetrics & Gynaecology, 2008, 115, 2Direct Link:
- 37, Hormones and breast cancer: can we use them in ways that could reduce the risk?, Oncology Reviews, 2008, 2, 3, 146
- 38, , Hormones in Wellness and Disease Prevention: Common Practices, Current State of the Evidence, and Questions for the Future, Primary Care: Clinics in Office Practice, 2008, 35, 4, 669
- 39, , , , , , , , , , , , In vivo estrogenic comparisons of Trifolium pratense (red clover) Humulus lupulus (hops), and the pure compounds isoxanthohumol and 8-prenylnaringenin, Chemico-Biological Interactions, 2008, 176, 1, 30
- 40, Intravaginal oestrogen and progestin administration: advantages and disadvantages, Best Practice & Research Clinical Obstetrics & Gynaecology, 2008, 22, 2, 391
- 41, Perils of Progestins: Increased Breast Cancer Risk Associated with Postmenopausal Hormone Replacement Therapy, Breast Diseases: A Year Book Quarterly, 2008, 19, 2, 123
- 42
- 43, PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes, PPAR Research, 2008, 2008, 1
- 44, , Traitement hormonal de la ménopause : pour, Gynécologie Obstétrique & Fertilité, 2008, 36, 1, 98
- 45, , , Transcriptional profiles of progestogen effects in the postmenopausal breast, Breast Cancer Research and Treatment, 2008, 114, 2, 233
- 46
- 47, , , , , , Association between premenopausal progestogen use and postmenopausal hormonal therapy in the GAZEL cohort, Maturitas, 2007, 58, 3, 216
- 48, , , , , , , , , , , , , Bioavailability and urinary excretion of isoflavones in humans: Effects of soy-based supplements formulation and equol production, Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 4, 1488
- 49, , Bioidentical Hormones for Menopausal Hormone Therapy: Variation on a Theme, Journal of General Internal Medicine, 2007, 22, 7, 1030
- 50, , Breast cancer from oral and transdermal estradiol: a cohort study of Finnish women, Women's Health, 2007, 3, 3, 321
- 51, Cancer du sein: les raisons d'une incidence en permanente augmentation, La Presse Médicale, 2007, 36, 2, 312
- 52, , Downgrading skin climacteric aging by hormone replacement therapy, Expert Review of Dermatology, 2007, 2, 4, 373
- 53, , , , , , , , , Good agreement between physician and self-reported hormone therapy data in a case–control study, Journal of Clinical Epidemiology, 2007, 60, 12, 1280
- 54, , , Hormonal therapy and depression: Are we overlooking an important therapeutic alternative?, Journal of Psychosomatic Research, 2007, 62, 4, 473
- 55, , , , , Hormone replacement therapy and breast cancer in former users of oral contraceptives—The Norwegian Women and Cancer study, International Journal of Cancer, 2007, 121, 3Direct Link:
- 56, , Hormone replacement therapy and breast cancer. The European view, European Clinics in Obstetrics and Gynaecology, 2007, 3, 1, 7
- 57, How fashions change in gynaecology and infertility, Reproductive BioMedicine Online, 2007, 14, 4, 536
- 58, , Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen, Expert Opinion on Investigational Drugs, 2007, 16, 12, 2005
- 59, Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy, Comptes Rendus Biologies, 2007, 330, 4, 347
- 60, , , , , , , Oral progestagens before menopause and breast cancer risk, British Journal of Cancer, 2007, 96, 5, 841
- 61, , , , Progesterone: Therapeutic opportunities for neuroprotection and myelin repair, Pharmacology & Therapeutics, 2007, 116, 1, 77
- 62, , , , , , , , , , , Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 624, 1-2, 88
- 63, , , , , Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study, Psychological Medicine, 2007, 37, 09, 1315
- 64, The discovery and mechanism of action of letrozole, Breast Cancer Research and Treatment, 2007, 105, S1, 7
- 65, , Traitement hormonal chez les femmes ménopausées: tous les traitements sont-ils équivalents?, Gynécologie Obstétrique & Fertilité, 2007, 35, 5, 388
- 66, , Traitement hormonal chez les femmes ménopausées: tous les traitements sont-ils équivalents? Toutes les patientes sont-elles identiques?, Gynécologie Obstétrique & Fertilité, 2007, 35, 6, 502
- 67, Traitement hormonal substitutif et vaisseaux: où en est-on en 2007?, Journal des Maladies Vasculaires, 2007, 32, 4-5, 190
- 68, , , Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study, Breast Cancer Research and Treatment, 2007, 107, 1, 103
- 69, A new ‘publication bias’: the mode of publication, Reproductive BioMedicine Online, 2006, 13, 5, 754
- 70, , , Breast Cancer Risk in Postmenopausal Women Using Estrogen-Only Therapy, Obstetrics & Gynecology, 2006, 108, 6, 1354
- 71, Climacteric Symptoms & Hormone Therapy, Journal of the Korean Medical Association, 2006, 49, 1, 11
- 72, , Current breast cancer risks of hormone replacement therapy in postmenopausal women, Expert Opinion on Pharmacotherapy, 2006, 7, 18, 2455
- 73, Dealing with the menopause: the French exception, Reproductive BioMedicine Online, 2006, 12, 1, 127
- 74, , , , , , Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys, Breast Cancer Research and Treatment, 2006, 101, 2, 125
- 75, , , , , , , , , Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26–28, 2006, International Journal of Gynecological Cancer, 2006, 16,Direct Link:
- 76, , Estrogen Carcinogenesis in Breast Cancer, New England Journal of Medicine, 2006, 354, 3, 270
- 77, , , , , , Exploration de la ménopause, Revue Francophone des Laboratoires, 2006, 2006, 379, 26
- 78, , , , Incidences and Trends of Second Cancers in Female Breast Cancer Patients: A Fixed Inception Cohort-based Analysis (United States), Cancer Causes & Control, 2006, 17, 4, 411
- 79, , Les isoflavones de soja dans le traitement de la ménopause, Phytothérapie, 2006, 4, 4, 172
- 80, Menopause: evidence-based practice, Best Practice & Research Clinical Obstetrics & Gynaecology, 2006, 20, 6, 799
- 81, , , Physiologic induction of puberty in Turner syndrome with very low-dose estradiol, International Congress Series, 2006, 1298, 71
- 82, , Place du traitement hormonal substitutif dans la prise en charge de l’ostéoporose postménopausique et la prévention du risque fracturaire, La Presse Médicale, 2006, 35, 10, 1557
- 83, , , , Propensity of gynaecologists towards osteoporosis management and treatment, Maturitas, 2006, 53, 4, 483
- 84, , , , , , , , , , Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT, Maturitas, 2006, 55, 1, 69
- 85, , , , Skin climacteric aging and hormone replacement therapy, Journal of Cosmetic Dermatology, 2006, 5, 1Direct Link:
- 86, Traitement hormonal et ostéoporose postménopausique, Revue du Rhumatisme, 2006, 73, 8, 812
- You have free access to this content87, , , , , , , , , Understanding the oestrogen action in experimental and clinical atherosclerosis, Fundamental & Clinical Pharmacology, 2006, 20, 6Direct Link:
- 88, , , , , , Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997, Maturitas, 2006, 53, 4, 462
- 89
- 90, , , , , , , , , , Estimated numbers of postmenopausal women treated by hormone therapy in France, Maturitas, 2005, 52, 3-4, 296
- 91
- 92, Le THS : abandon ? Le THM : avenir…, Gynécologie Obstétrique & Fertilité, 2005, 33, 11, 847
- 93, , , , , Méthodologie de l’enquête MISSION (Ménopause, rISque de cancer du SeIn, mOrbidité et prévaleNce), Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 2005, 34, 7, 658
- 94, , , , , , , , , New evidence regarding hormone replacement therapies is urgently required, Maturitas, 2005, 52, 1, 1
- 95, Postmenopausal hormone therapy and breast cancer: What is the problem?, Maturitas, 2005, 51, 1, 75
- 96, , , , Pregnancy, progesterone and progestins in relation to breast cancer risk, The Journal of Steroid Biochemistry and Molecular Biology, 2005, 97, 5, 441
- 97, , , , , , , , , , , , , , , , , Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9–16, 2003, Bellagio, Italy, European Journal of Haematology, 2005, 75,Direct Link: